Results 21 to 30 of about 8,073,410 (232)
Management of ANCA-associated vasculitis: Current trends and future prospects [PDF]
Sally Hamour, Alan D Salama, Charles D PuseyImperial College Kidney and Transplant Institute, Imperial College, London, UKAbstract: The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are a spectrum of heterogeneous autoimmune diseases ...
Hamour, S +5 more
core +1 more source
Background/Purpose: A reliable noninvasive prognostic factor of ANCA-associated vasculitis (AAV) is still lacking, but little research has focused on the value of MPO-ANCA titers in patients with active vasculitis.
Chieh-Li Yen +8 more
doaj +1 more source
The aim of the study – to determine the diagnostic value of serum levels of endothelin-1, alpha-actin-2 and elastin in patients with primary systemic vasculitis. Materials and methods.
L. B. Petelytska, O. B. Yaremenko
doaj +1 more source
Complement in ANCA-Associated Vasculitis
Antineutrophil cytoplasmic autoantibodies (ANCA) are the likely cause for necrotizing small vessel vasculitis and crescentic glomerulonephritis. Unlike other forms of crescentic glomerulonephritis induced by immune complexes or anti-glomerular basement membrane (anti-GBM) antibodies that have conspicuous vessel wall immunoglobulin and complement, there
J, Charles Jennette +2 more
openaire +3 more sources
Background: The ear, nose and throat region has been reported to be one of the commonest sites involved in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis diseases and often precedes the diagnosis of ANCA–associated vasculitis by many ...
Alfonso Luca Pendolino +6 more
doaj +1 more source
What is new in the management of rapidly progressive glomerulonephritis? [PDF]
Rapidly progressive glomerulonephritis (RPGN) results from severe crescentic damage to glomeruli and leads to irreversible kidney failure if not diagnosed and managed in a timely fashion.
Greenhall, GHB +3 more
core +1 more source
Obinutuzumab as treatment for ANCA-associated vasculitis
International audienceAbstract Objectives Rituximab is a standard of care therapy for patients with ANCA-associated vasculitis. When rituximab is contraindicated, or in the case of refractory disease, other treatments are needed.
Langford, Carol +6 more
core +1 more source
Background Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis is a term used to describe systemic vasculitides that affect small and medium-sized blood vessels.
Alexandra Theisen +2 more
doaj +1 more source
Rapid progression of large intracranial cerebral artery involvement in a patient with myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis [PDF]
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic necrotizing vasculitis that predominantly affects small vessels of the body. The two most common ANCAs are myeloperoxidase ANCA and proteinase 3 ANCA.
Jihee Ko, Jay Chol Choi
doaj +1 more source
ANCA-associated renal vasculitis [PDF]
The hemoglobin level was 8.8 g/dL with normal indices. The CASE PRESENTATION erythrocyte sedimentation rate was 70 mm/hr. C-reactive proA 62-year-old white woman presented to another hospital tein was 30 mg/L (normal 10 mg/L), and she had a positive with a five-week history of profound malaise and small joint antineutrophil cytoplasmic antibody (ANCA ...
openaire +2 more sources

